MICs of fluconazole and amphotericin B were determined independently for 100 coded yeast isolates by each of six laboratories to determine reproducibility of results by using a colorimetric oxidation-reduction-based broth microdilution test. In addition, each site tested five quality control isolates on at least four different occasions during the study. Results agreed within a three-dilution range (mode + 1 log2 dilution) for 96.2% of fluconazole tests and 92.7% of amphotericin B tests. Agreement among tests with the quality control isolates was 99.4% with fluconazole and 98.6% with amphotericin B. These results indicate that the colorimetric microdilution method is reproducible among laboratories.
Serious fungal infections are increasing rapidly in incidence (3, 15, 17, 18, 20, 21, 26, 29, 30) . Yeast isolates may account for up to 10% of all nosocomial bloodstream infections and are a serious source of morbidity and mortality among some patient populations (3, 17, 20, 21, 29, 30) .
Until recently, the selection of antifungal agents was limited largely to amphotericin B and 5-fluorocytosine (4, 26) . Introduction of other agents, particularly the imidazole and triazole compounds, has increased the antifungal armamentarium markedly (2, 4, 5, 13, 26, 31) . The increase in the number of antifungal agents, coupled with an apparent increase in infections caused by Candida species other than C. albicans and the variable susceptibilities of these organisms to the currently available antifungal agents, places a greater emphasis on in vitro susceptibility testing to guide therapeutic decisions (1-3, 5, 10, 12, 14, 16, 24, 25, 28, 31) .
Methods for performing antifungal susceptibility testing have been in existence for many years, but these methods have suffered from lack of standardization and, consequently, poor reproducibility among laboratories (6, 8, 9-12, 24, 25) . Through a consensus process, the National Committee for Clinical Laboratory Standards (NCCLS) Subcommittee on Antifungal Susceptibility Tests has developed a proposed reference method for broth macrodilution testing of yeasts (NCCLS M27-P) (19) . Because the macrodilution format is too cumbersome for use in most clinical laboratories, efforts have been focused recently on adapting the NCCLS M27-P method to a format that may be more practical and user friendly in the clinical laboratory (7, 8, (22) (23) (24) . Recently, we have proposed the use of a colorimetric MIC method using an oxidation-reduction indicator (Alamar Biosciences, Inc., Sacramento, Calif.) to provide an objective, easy to read MIC in a microdilution format (22, 23) . Excellent agreement (.94%) was observed between MICs by the reference method and the colorimetric microdilution MICs when tested in a single laboratory (22, 23 (9) . The isolates were identified by standard methods (27) addition of 100 ,ul of the inoculum suspension. The trays were incubated in air at 35°C for 24 h. The colorimetric MIC endpoints were read visually by observing a change in color from blue (negative) to red (positive). The MIC was defined as the lowest concentration of antifungal drug preventing the development of a red color (first blue well) (22, 23) . Generally, the colorimetric endpoints were sharp; however, occasional isolates produced a purple color in transition from blue to red. In such instances, the endpoint was read as the concentration at which the color changed from purple to red. QC. Quality control (QC) was ensured by testing the following strains at least four times throughout the course of the study: Saccharomyces cerevisiae ATCC 9763, C. albicans ATCC 24433, C. krusei ATCC 6258, C. parapsilosis ATCC 22019, and C. tropicalis ATCC 750.
Study design and analysis. Six laboratories (referred to as laboratories 1 to 6) participated in the study. Each laboratory received individual subcultures of the test and QC isolates, each of which was identified by a coded number. In addition, the laboratories were sent dried microdilution trays and sufficient buffered RPMI 1640 test medium to perform the study. All laboratories tested each isolate once without retesting (a total of 600 tests per drug). QC isolates were tested a minimum of four times each in the six laboratories. Results were recorded on data sheets supplied to each laboratory and were submitted to a coordinating laboratory for analysis.
Interlaboratory agreement was determined by calculating the percentage of MICs within a three-dilution range for each isolate and of each antifungal agent. Generally, the threedilution range constituted the mode ± 1 log2 dilution (96% of drug-organism combinations); however, for some isolates without a clear modal MIC, it was the three-dilution range that encompassed the largest number of MICs reported. The analysis of the MIC data included both MICs for which endpoints were obtained (on-scale results) and those which were off scale. The high off-scale MICs (>4.0 ,ug/ml for amphotericin B and >256 ,ug/ml for fluconazole) were converted to the next highest concentration (8.0 and 512 ,ug/ml, respectively), and the low off-scale MICs (0.03 and s0. 12 ,ug/ml, respectively) were left unchanged. Overall, .95% of Table 3 . Overall agreement among laboratories was 92.7% for amphotericin B and 96.2% for fluconazole. Regarding the individual species, only C. lusitaniae (amphotericin B and fluconazole) and C. parapsilosis (amphotericin B only) had levels of agreement of <94%. It was noted that one of the reasons for a lower level of agreement with C lusitaniae and C. parapsilosis was that some of the laboratories reported very low 24-h MICs for amphotericin B and/or fluconazole, whereas other laboratories reported MICs that were four to five wells higher for the same strains. Because this was not observed with other species, one explanation could be poor or inconsistent growth of C. lusitaniae and C. parapsilosis in the RPMI test medium.
Further analysis of the basis for the lower agreement observed with C. lusitaniae and C. parapsilosis was undertaken with data from one of the participating laboratories (laboratory 4) from which both 24- and 48-h MICs were obtained. The effect of extending the duration of incubation to 48 h on amphotericin B and fluconazole MICs for C. lusitaniae and C. parapsilosis is shown in Table 4 . For C. lusitaniae, the MICs of both amphotericin B and fluconazole increased substantially b n, total number of isolates tested. Table 4 . C. albicans grows very well in RPMI medium, and the interlaboratory agreement was excellent for this species (Table 3) . In contrast to C. lusitaniae and C. parapsilosis, the MICs for C. albicans did not change substantially with extended incubation.
DISCUSSION
The results reported herein extend our previous observations and document that excellent intra-and interlaboratory agreement can be obtained with the colorimetric microdilution method for determination of in vitro susceptibilities of Candida spp. to amphotericin B and fluconazole. By testing a panel of five QC isolates on several occasions throughout the study, we have documented excellent intralaboratory reproducibility and comparable performance with the colorimetric microdilution test among all six laboratories. The QC strains included in this study were not those recommended in M27-P (19) . Alternative strains were selected for this study because three of the six isolates recommended in M27-P had target MICs that were either off scale or clustered at the low end of the concentration range (19) . The strains used in the present study were selected to include a wider range of on-scale MICs, to represent a greater number of yeast species, and to avoid the inclusion of pathogenic species (e.g., Cryptococcus neoformans) as QC isolates. Further evaluation of these strains as candidate QC isolates is indicated.
The panel of 100 clinical isolates tested once in each laboratory allowed us to evaluate the feasibility of the colorimetric microdilution method for performing antifungal susceptibility tests and to determine the reproducibility of this method among laboratories. Determination of MIC endpoints after a 24-h incubation resulted in excellent agreement among laboratories for both amphotericin B and fluconazole. Previously, we have shown that the 24-h reading of colorimetric microdilution panels produced results comparable to 48-h readings of the macrodilution reference method (M27-P) for testing C. albicans and fluconazole (23) . The present study extends these observations to include amphotericin B and other Candida species.
Clearly, an earlier MIC reading is more desirable clinically; however, we observed some problems with the 24-h endpoint when testing C. lusitaniae and C. parapsilosis. The agreement among laboratories was considerably lower for these two species than with other test isolates. Further investigation at one of the participating laboratories suggested suboptimal growth of C. lusitaniae and C. parapsilosis in RPMI medium at 24 h. Incubation for an additional 24 h resulted in increased growth and a significant increase in the MICs of fluconazole and amphotericin B (Table 4) . Although confirmatory experiments were not performed in other laboratories, these data suggest that for certain species a longer incubation or an alternative medium supporting better growth may be necessary to provide optimal test conditions.
The increase in MICs of amphotericin B for several strains of C. lusitaniae from .0.03 ,ug/ml at 24 h of incubation to 4.0 ,ug/ml at 48 h (Table 4) is of particular interest given the suggestion by Rex et al. (25) that the proposed NCCLS method (M27-P) does not appear to be well suited to detect amphotericin B resistance. By extending incubation with the colorimetric microdilution method, the MICs of amphotericin B for C. lusitaniae were clearly higher than those for C. albicans or C. parapsilosis ( 
